Allergovit 6-grasses
Phase 3Biologic
Allergovit 6-grasses is one of 29 biologic programs targeting Conjunctivitis. It is currently in Phase 3.
1
Indications
2
Total Trials
0
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
52 competitors in Conjunctivitis
#DrugCompanyPhaseTrials
1Avelox
BayerApproved
Neoral
NovartisApproved
Lotemax
BBausch & Lomb Incorporated
Approved
Tobrex
VViatris Specialty LLC
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levaquin
WWim Janssens
Approved
Prograf
VVeloxis Pharmaceuticals
Approved
Cytovene
EExela Pharma Sciences, LLC.
Phase 3
Claritin
PPerrigo Company
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Allergovit 6-grasses. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- AAllergopharma GmbH & Co. KG